Insmed Inc (INSM)vsOKYO Pharma Ltd ADR (OKYO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
OKYO
OKYO Pharma Ltd ADR
$1.58
-1.25%
HEALTHCARE · Cap: $89.89M
Smart Verdict
WallStSmart Research — data-driven comparison
OKYO leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
OKYO
Avoid16
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : OKYO
The strongest argument for OKYO centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : OKYO
The primary concerns for OKYO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while OKYO is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
OKYO generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
OKYO Pharma Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
OKYO Pharma Limited, a preclinical biopharmaceutical company, is engaged in developing therapies for patients suffering from inflammatory eye diseases and eye pain in the UK. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?